UroAmp
Bladder Cancer (Minimal Residual Disease & Recurrence Monitoring)
Key Facts
About Convergent Genomics
Convergent Genomics is a private, commercial-stage diagnostic company developing non-invasive liquid biopsy tests for cancer detection and monitoring. Its lead product, UroAmp, is a genomic urine test for detecting Minimal Residual Disease (MRD) and recurrence in bladder cancer patients, leveraging next-generation sequencing and machine learning. The company is led by a team of cancer biologists, urologic oncologists, and data scientists, and its technology aims to shift cancer care from reactive treatment to proactive prediction and early intervention. Convergent Genomics appears to be in an early revenue phase, commercializing its UroAmp test while building clinical evidence.
View full company profile